Advertisement

Pharmacy World and Science

, Volume 15, Issue 6, pp 252–256 | Cite as

Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment

  • J. P. Schouten
  • G. Voorhorst
  • A. R. Helbing
  • J. W. Janssen
  • P. P. N. M. Diderich
  • C. T. Op de Hoek
Articles

Abstract

The purpose of this study was to investigate whether chronic subcutaneous administration of epoetin has an influence on its pharmacokinetics in patients with chronic renal failure and anaemia. 14 Patients were included in the study. The data of 8 patients could be evaluated at the end of the study. All patients were on maintenance haemodialysis. The pharmacokinetic profile of epoetin was studied directly after the first subcutaneous administration of 60 U/kg body weight. Patients were further treated with epoetin to maintain haemoglobin concentration between 6.0 and 6.5 mmol/l. After about one year of treatment the pharmacokinetic profile was studied again, using the same dosage. Between both profiles no significant differences (paired Student's t-test) were found in the pharmacokinetic parameters studied: absorption half-life, time to maximum concentration, maximum concentration, elimination half-life, area under the curve and mean residence time. However, in individual patients large differences may be found.

Keywords

Anemia Epoetin Hemodialysis Injections, subcutaneous Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eschbach JW, Adamson JW. Modern aspects of the pathophysiology of renal anemia. Contrib Nephrol 1988;66:63–70.Google Scholar
  2. 2.
    Kampf D, Kahl A, Passlick J, Pustelnik A, Eckrardt K-U, Ehmer B, et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Contrib Nephrol 1989;76:106–11.Google Scholar
  3. 3.
    Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles CA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989;1:425–7.Google Scholar
  4. 4.
    Neumayer HH, Brockmöller J, Fritschka E, Roots I, Scigalla P, Wattenberg M. Pharmacokinetics of recombinant human erythropoietin after subcutaneous administration and in long-term intravenous treatment in patients on maintenance hemodialysis. Contrib Nephrol 1989;76:131–42.Google Scholar
  5. 5.
    Bommer J, Ritz E, Weinreich Th, Bommer G, Ziegler T. Subcutaneous erythropoietin [letter]. Lancet 1988;2:406–7.Google Scholar
  6. 6.
    Grannolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S. Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol 1989;76:143–8.Google Scholar
  7. 7.
    Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979;93:449–58.Google Scholar
  8. 8.
    Sun CH, Ward HJ, Paul WL, Koyle MA, Yanagawa N, Lee DBN. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989;321:151–7.Google Scholar

Copyright information

© Royal Dutch Association for the Advancement of Pharmacy 1993

Authors and Affiliations

  • J. P. Schouten
    • 1
  • G. Voorhorst
    • 1
  • A. R. Helbing
    • 2
  • J. W. Janssen
    • 2
  • P. P. N. M. Diderich
    • 3
  • C. T. Op de Hoek
    • 4
  1. 1.Department of PharmacySint Franciscus GasthuisPM RotterdamThe Netherlands
  2. 2.Department of Clinical Chemistry and HaematologySint Franciscus GasthuisThe Netherlands
  3. 3.Department of NephrologySint Franciscus GasthuisThe Netherlands
  4. 4.Diatel RijnmondTA Capelle aan den Ijssel

Personalised recommendations